Ratings Quantum-Si incorporated

Equities

QSI

US74765K1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
0.9557 ^USD	+2.84%		+2.28%	-52.45%

May. 30	Quantum-Si Incorporated Announces Board Changes	CI
May. 15	Transcript : Quantum-Si incorporated - Shareholder/Analyst Call

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
QUANTUM-SI INCORPORATED	-52.45%	136M	-
MODERNA, INC.	+17.09%	44.63B	B-
LONZA GROUP AG	+45.66%	40.46B	A
IQVIA HOLDINGS INC.	-9.70%	38.07B	B
ALNYLAM PHARMACEUTICALS, INC.	+33.28%	32.27B	B
CELLTRION, INC.	-8.98%	27.3B	C
ICON PUBLIC LIMITED COMPANY	+13.37%	26.53B	B-
UNITED THERAPEUTICS CORPORATION	+44.11%	14.06B	B+
MEDPACE HOLDINGS, INC.	+32.33%	12.54B	C+
BIO-TECHNE CORPORATION	-7.26%	11.28B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes